DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lfcznc/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Breast Cancer Overview
- Therapeutics Development
- Breast Cancer - Therapeutics under Development by Companies
- Breast Cancer - Therapeutics under Investigation by Universities/Institutes
- Breast Cancer - Pipeline Products Glance
- Breast Cancer - Products under Development by Companies
- Breast Cancer - Products under Investigation by Universities/Institutes
- Breast Cancer - Companies Involved in Therapeutics Development
- Breast Cancer - Therapeutics Assessment
- Drug Profiles
- Breast Cancer - Recent Pipeline Updates
- Breast Cancer - Dormant Projects
- Breast Cancer - Discontinued Products
- Breast Cancer - Product Development Milestones
For more information visit http://www.researchandmarkets.com/research/lfcznc/breast_cancer